Quality of Life Outcomes in Patients With Sinonasal Malignancy After Definitive Treatment

xlomafota13 shared this article with you from Inoreader Quality of Life Outcomes in Patients With Sinonasal Malignancy After Definitive Treatment Via The Laryngoscope Objectives/Hypothesis To describe multidimensional quality of life (QOL) outcomes in patients with sinonasal malignancies (SNM). To elucidate factors predicting worse QOL in this population. Study Design Retrospective chart review at tertiary institution. Methods A retrospective chart review on patients treated for SNM from 2006 to 2019 at a tertiary medical center was conducted. QOL outcomes were measured using the Hospital Anxiety and Depression Scale (HADS) and the Functional Assessment Cancer Therapy – Nasopharynx (FACT-NP) score. A stepwise multiple linear regression analysis was conducted to assess factors predicting worse QOL. Results Eighty-one patients met inclusion criteria. Twelve (14.8%) patients had a subscale score >11 for anxiety (HADS-A) or depression (HADS-D) indicating significant anxiety or depression, at a median of 24 (8–68.5) months post treatment. The median FACT-NP total score was 136 (110–152). On multivariable analysis, advanced T classification, single status, and worse social support survey score were significant predictors of worse HADS score. Worse social support survey score was a significant predictor of worse total FACT-NP score. Conclusion After adjusting for confounders, at a median of 24 months after completion of definitive therapy for SNM, advanced T classification and single relationship status were found to be significant predictors of anxiety and depression (based on HADS). A worse social support survey score was associated with worse anxiety, depression, and QOL (based on HADS and FACT-NP). Identifying these factors early may help to guide treatment and psychiatric referral to at-risk individuals after the treatment of SNM. Level of Evidence 3 Laryngoscope, 131:E2212–E2221, 2021 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.